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Differential depression of 
neuronal network activity by 
midazolam and its main metabolite 
1-hydroxymidazolam in cultured 
neocortical slices
Monika Balk1,5, Harald Hentschke  1, Uwe Rudolph2,3, Bernd Antkowiak1,4 & Berthold 
Drexler1
The benzodiazepine midazolam is widely used in critical care medicine. Midazolam has a clinically 
active metabolite, 1-hydroxymidazolam. The contribution of 1-hydroxymidazolam to the effects of 
midazolam is controversial. The aim of the current study was to compare the actions of midazolam and 
1-hydroxymidazolam on network activity of cortical neurons. Midazolam depressed neuronal activity 
at a low concentration of 5 nM. When midazolam concentration was increased, it depressed neuronal 
discharge rates in a biphasic manner. In comparison, 1-hydroxymidazolam did not depress the cortical 
network activity at low nanomolar concentrations. Higher concentrations of 1-hydroxymidazolam 
consistently inhibited neuronal activity. Moreover, midazolam shortened cortical up states at low, 
but not at high concentrations, while the opposite effect was observed with 1-hydroxymidazolam. 
The network depressant action of midazolam at low concentrations was absent in slices from GABAA 
receptor α1(H101R)mutant mice. The α1(H101R)mutation renders α1-subunit containing GABAA 
receptors insensitive towards benzodiazepines. This GABAA receptor subtype is thought to mediate 
sedation. As midazolam is more potent than its metabolite 1-hydroxymidazolam, the major clinical 
effects are thus likely caused by midazolam itself. However, 1-hydroxymidazolam could add to the 
effects of midazolam, especially after the application of high doses of midazolam, and in case of 
impaired drug metabolism.
Midazolam is a commonly used benzodiazepine in anaesthesia and intensive care medicine. Midazolam has a 
clinical active metabolite: 1-hydroxymidazolam, which is, like the parent drug midazolam a neuronal depressant 
drug. However, 1-hydroxymidazolam’s contribution to the depression of neuronal activity and thus its clinical 
relevance still remains a matter of debate. There are numerous studies in which the statements concerning the 
contribution of 1-hydroxymidazolam to the clinical actions of midazolam range from “almost equipotent” to “no 
major contributing factor”1–5. In addition, Crevoisier et al. have demonstrated that cognitive and motor impair-
ments induced by midazolam are different after oral or intravenous application, an observation that was attrib-
uted to the relatively higher amount of 1-hydroxymidazolam after oral administration6.
The current study was therefore designed to directly compare the effects of midazolam and 
1-hydroxymidazolam on the activity of neocortical neurons in organotypic slice cultures, a model system in 
which, to the best of our knowledge, there is no relevant metabolism from midazolam to 1-hydroxymidazolam.
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Basically, benzodiazepines like midazolam predominantly act via GABAA receptors harbouring either an α1, 
α2, α3 or α5-subunit. About 40% of all GABAA receptors in the brain contain α1-subunits, making them the major 
GABAA receptor subtype in the brain7. Mice carrying a point mutation in the α1 subunit of the GABAA receptor 
at position 101 are resistant to the sedative action of diazepam, indicating that benzodiazepine-induced sedation 
is predominantly mediated via GABAA receptors containing the α1-subunit8, 9. Moreover, it was suggested that 
sedation with diazepam depends on GABAA receptors located on glutamatergic neurons in the cerebral cortex10. 
On the cellular level, this molecular action of diazepam translates into a significant depression of cortical network 
action potential firing11. Therefore, in order to examine the contribution of α1-containing GABAA receptors to 
this phenomenon, in the current study clinically relevant concentrations of midazolam were also tested in neo-
cortical slice cultures from GABAA receptor α1(H101R) knock-in mice.
Results
Neuronal activity of organotypic neocortical slice cultures under control conditions. 
Spontaneous firing patterns from neocortical organotypic slice cultures were characterized by phases of high neu-
ronal activity (up states) separated by periods of neuronal silence. A typical extracellular recording is displayed 
in Fig. 1. To analyse changes of discharge rates in the presence of drugs we used the following parameters: i) the 
action potential firing rate and ii) the length of up states. Up states of neocortical slice cultures are characterized 
by high frequency action potential firing at the beginning of the up state, which is then gradually decreasing over 
time12. The median of the spontaneous action potential firing rate (in C57/BL6J mice) was at 10.12 Hz; interquar-
tile range (iqr): 12.92; (number of recordings n = 481).
Effects of midazolam in organotypic slice cultures (C57BL/6J). Midazolam in a concentration range 
from 5 nM to 100 µM inhibited the neuronal firing rate in a biphasic manner. From 5 nM to 1 µM, midazolam 
significantly depressed action potential firing. However, the inhibitory action of midazolam did not rise continu-
ously with increasing concentrations. Actually, 500 nM and 1 µM midazolam depressed the neuronal activity only 
slightly less than the administration of 100 nM midazolam. Though, raising the concentration of midazolam to 
25 µM and beyond led to a stronger depression, which was significantly different from the concentration range of 
5 nM to 1 µM (Fig. 2A, Kruskal-Wallis test and post-hoc Bonferroni analysis).
Even a low concentration of 5 nM midazolam induced a significant change in neuronal activity (median 76%, 
iqr 26%; p < 0.001; n = 28; Mann-Whitney U test).
To further elucidate the actions of midazolam at 5 nM we calculated a peri-event time histogram (PETH) 
for the first 1000 ms of the average up state. The sham application of ACSF only led to negligible changes at the 
beginning of the up states (Fig. 2B). By comparison, 5 nM midazolam consistently inhibited action potential firing 
significantly over the entire first 1000 ms of the average up state (Fig. 2C).
To test whether this action of midazolam is mediated via the classical benzodiazepine binding site of the 
GABAA receptor, we performed experiments with flumazenil, a selective antagonist at the benzodiazepine bind-
ing site of the GABAA receptor13, 14. As shown in Fig. 2D,E the network depressing actions of midazolam (5 nM 
and 50 nM) indeed proved to be almost completely absent when administering 50 nM flumazenil.
Effects of 1-hydroxmidazolam in organotypic cultures and comparison to those of mida-
zolam. To compare the actions of midazolam with those of 1-hydroxymidazolam we tested a con-
centration range of 1-hydroxymidazolam from 5 nM to 1 µM, because the in vivo concentration range of 
1-hydroxymidazolam is lower than that of midazolam itself 3.
The concentration response relationship for 1-hydroxymidazolam is displayed in Fig. 3A. In contrast to mida-
zolam, we could not find an inhibitory effect for 1-hydroxymidazolam at 5 nM and 50 nM. Only at concentrations 
of 100 nM or higher 1-hydroxymidazolam did induce a significant inhibition (median 60%, iqr 69; p < 0.001). 
Figure 1. Original recording from a neocortical slice culture. An extracellular recording from an organotypic 
murine slice culture is displayed at three different time scales. The recorded signal was band-pass filtered (200–
2000 Hz) to separate action potentials from local field potentials. Upper row: One minute recording of neuronal 
activity: eleven up states (phases of high frequency action potential firing) are separated by neuronal silence 
(down states). Middle row: Ten seconds of the trace given above at higher temporal resolution. Two up states 
can be identified, halted by neuronal silence. Lower trace: a single up state at high temporal resolution, single 
action potentials can be identified.
www.nature.com/scientificreports/
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Figure 2. The effects of midazolam on global neuronal activity. (A) Midazolam inhibited the action potential 
firing rate of neocortical cultures in a biphasic manner. Over a wide concentration range starting at 5 nM up 
to 12.5 μM the residual activity roughly averaged 60% (*p < 0.001 compared with ACSF sham application, 
light grey). When increasing the concentration to 25 μM a further depression was observed, statistically 
different compared with the former concentration range (#p < 0.001, dark grey) (n/concentration: 27–50). 
All data are normalized to the median of the ACSF sham application. The dotted line marks 100%, i.e. no 
difference compared to ACSF sham application (statistical analysis: Kruskal-Wallis test with post-hoc analysis 
(Bonferroni) and Mann-Whitney U test for testing between two different groups). (B–D) Effects of midazolam 
on neuronal up states displayed as peri-event time histogram (PETH). To illustrate the differences, the effect 
www.nature.com/scientificreports/
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Again, unlike midazolam, 1-hydroxymidazolam caused a steady increase in the depression of network activity 
with increasing concentrations of up to 1 µM (median 34%; iqr 33; p < 0.001).
To test whether the effect of 1-hydroxymidazolam is also mediated by the classical benzodiazepine binding 
site, we measured the network activity after administering a combination of 1 µM 1-hydroxymidazolam with 
1 µM flumazenil. The depression of neocortical activity triggered by 1-hydroxymidazolam was almost completely 
antagonized by flumazenil (Fig. 3B).
To further explain the quantitative differences of action between the two compounds in detail, we calculated 
PETHs for 1-hydroxymidazolam. As can be seen in Fig. 3C, 1-hydroxymidazolam did not show any inhibitory 
effect at a concentration of 5 nM. At a higher concentration (100 nM), 1-hydroxymidazolam was able to depress 
cortical activity, but its effect was only significant during the first 100 ms of the up states (Fig. 3D). A compari-
son of the actions of the parent drug midazolam and its metabolite 1-hydroxymidazolam is displayed in Fig. 4. 
Due to the biphasic nature of midazolam’s concentration response curve, we compared only concentrations up 
to the border of the wide ‘plateau’ region of the concentration response curves (1 µM of both midazolam and 
1-hydroxymidazolam). As can be seen in the plot (Fig. 4A), IC50 values of both concentration response curves 
differed by over an order of magnitude (IC50 in nM with 95% CI: midazolam, 3.6 [0.9 6.4]; 1-hydroxymidazolam: 
84.2 [48.7 119.8]; extra sums-of-squares test (see Methods for details): F(2,242) = 11.98, p = 8.6 * 10−6).
To further investigate the differences in action of midazolam and 1-hydroxymidazolam we analysed the length 
of up states. Under control conditions, the median length of up states was 664 ms (iqr: 2400). When midazolam 
was administered at low concentrations, it shortened the length of up states, while at 500 nM and 1 µM this effect 
was completely absent. On the other hand, 1-hydroxymidazolam only reduced the length of up states significantly 
at 500 nM and 1 µM (Fig. 4B). It is obvious that midazolam and 1-hydroxymidazolam affected up state length in 
quite different ways: while midazolam shortened up state length particularly at concentrations below 0.5 µM, 
1-hydroxymidazolam did so only at concentrations above 0.1 µM (Fig. 4B). Statistical analysis (see Methods) 
confirmed this impression (two-way ANOVA of Box-Cox transformed data, interaction effect: F(4,289) = 14.2, 
p = 1.4 * 10−10, eta squared with 95% CI = 0.15 [0.09 0.25]).
To further elucidate the actions of midazolam and 1-hydroxymidazolam at the synaptic level, we performed 
patch-clamp recordings in neocortical slice cultures from wild-type C57BL/6J mice. In a first set of experiments 
the effects on phasic inhibition were tested by recording miniature IPSCs from pyramidal neurons. To quan-
tify drug actions on synaptical inhibition we used the total charge transfer, calculated as the area under the 
averaged IPSC multiplied by the frequency of IPSCs. Midazolam at a concentration of 50 nM increased total 
charge transfer by 71.6 ± 27.7% (n = 11, p = 0.045, t-test compared to sham application). At the same concen-
tration, 1-hydroxymidazolam appeared to increase total charge transfer to a lesser extent, but this effect was 
not significant (40.4 ± 24.3%, n = 15, p = 0.22, t-test compared to sham application, see Fig. 5A,B). In a sec-
ond set of experiments the actions of midazolam and 1-hydroxymidazolam on tonic inhibition were studied. 
For this purpose, neurons were additionally perfused with 20 µM bicuculline. Midazolam (50 nM) induced a 
tonic current of 16.87 ± 4.04 pA (n = 9, Fig. 5C,D), whereas 50 nM of 1-hydroxymidazolam induced a tonic 
current of 18.81 ± 4.57 pA (n = 12). However, both values were not significantly different from the basic tonic 
current induced in the presence of bicuculline and sham application (14.04 ± 5.87 pA, n = 7, one-way ANOVA, 
Fig. 5C,D).
The role of α1-subunit containing GABAA receptors for the actions of midazolam. Previous 
studies showed that cortical GABAA receptors containing α1-subunits are an important target in mediating 
benzodiazepine-induced sedation9, 10, 15.
To test the impact of cortical α1-containing GABAA receptors for midazolam we carried out experiments in 
cortical cultures derived from GABAAR α1(H101R) knock-in mice, in which α1-containing GABAA receptors are 
insensitive to benzodiazepines, including midazolam16. The basal activity of cultures derived from α1(H101R)
knock-in mice was 16.64 Hz; 14.87 (median, iqr, n = 136). This value was slightly higher than the value obtained 
with wild-type mice. However, when comparing PETH of the averaged up states, no differences could be detected 
between wild-type and α1(H101R) mice (Fig. 6A).
As can be seen in Fig. 6B,D, we were not able to determine any significant inhibitory effect in neocortical tis-
sue cultures derived from α1(H101R)knock-in mice for concentrations of 5 nM and 10 nM midazolam, neither 
during up states nor for the overall action potential firing rate. Only at a concentration of 100 nM midazolam 
did induce significant depression during phases of high neuronal activity (Fig. 6C). The concentration response 
relationship (see Fig. 6D) illustrates that only 100 nM and 1 µM midazolam caused a significant reduction of the 
action potential firing rate (median 64%; iqr 33; p < 0.001; median 63%; iqr 52; p = 0.001; Mann-Whitney U test). 
size (Hedges’ g including the 95% confidence interval) is given below the PETH. Effects can be regarded as 
significantly different, if the 95% confidence interval does not cross the zero line. (B) Time-dependant changes 
of neuronal activity under control condition (dark blue) and ACSF sham application (light blue). Besides a 
negligible reduction of neuronal activity at around 15 ms after the beginning of the up state, the action potential 
firing did not change over time during ACSF sham application. (C) Actions of midazolam at a concentration of 
5 nM (red, n = 28) versus control condition (dark blue). The effect size diagram illustrates that 5 nM midazolam 
continuously induced a significant inhibition during the first 1000 ms of the up state. (D) Effect of midazolam 
at a concentration of 5 nM in the additional presence of flumazenil (50 nM, orange, n = 28) versus control 
condition (dark blue). The effect size diagram displays that the significant inhibition during the first 1000 ms 
of the up state is absent in the presence of flumazenil. (E) Left box plot shows the normalized action potential 
firing in the presence of 50 nM midazolam alone. Right box plot shows the normalized firing rate after the 
combined application of 50 nM midazolam and 50 nM flumazenil (*p < 0.001).
www.nature.com/scientificreports/
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When comparing the effects of midazolam in α1(H101R) mice to those seen in wild-type mice, we observed that 
the inhibitory action of midazolam once again did not increase steadily with increasing concentrations. The con-
centration response relationship curves nearly run parallel to each other (Fig. 6E).
Discussion
Midazolam is metabolized into an active metabolite, 1-hydroxymidazolam. However, 1-hydroxymidazolam’s con-
tribution to the neuronal depressant actions of midazolam is complex and still poorly understood1–5.
Within the central nervous system the neocortex seems to be the major target in mediating sedation by ben-
zodiazepines10, 17. However, to date only little is known about the potentially differential effects of midazolam and 
1-hydroxymidazolam on neuronal activity in this region of the brain. Therefore, in the present study we set out to 
compare the potency and characteristics of midazolam and 1-hydroxymidazolam to inhibit spontaneous cortical 
activity. We observed that midazolam, acting mainly via α1-containing GABAA receptors, is by far more potent 
than 1-hydroxymidazolam and that midazolam and 1-hydroxymidazolam act quantitatively and qualitatively 
different.
Figure 3. Effects of 1-hydroxymidazolam in neocortical slice cultures from wild-type mice. (A) Effects of 
1-hydroxymidazolam on cortical network activity. 1-hydroxymidazolam did not induce significant changes 
in the neuronal action potential firing rate at low concentrations (5 nM and 50 nM). Only at concentrations 
ranging from 100 nM to 1 μM a significant inhibition of the action potential firing rate could be observed. Note 
that the depressing effect steadily rose by increasing the concentration of 1-hydroxymidazolam (*p < 0.001; 
Kruskal-Wallis test, post-hoc analysis (Bonferroni) followed by Mann-Whitney U test). (B) Actions of 
1-hydroxymidazolam in the presence of the benzodiazepine antagonist flumazenil. Left box plot shows the 
normalized firing rate of 1 μM 1-hydroxymidazolam, right box plot shows the normalized firing rate after the 
combined application of 1 μM 1-hydroxymidazolam and 1 μM flumazenil (*p < 0.001). (C) PETH showing the 
effects of 5 nM 1-hydroxymidazolam (magenta, n = 34) versus control condition (dark blue). Unlike midazolam, 
1-hydroxymidazolam did not depress neuronal activity during up states at low concentrations. For the effect of 
midazolam at the corresponding concentration please see Fig. 1C. (D) Actions of 100 nM 1-hydroxymidazolam 
(magenta, n = 34), versus control condition (dark blue) given as PETH.
www.nature.com/scientificreports/
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Midazolam depresses cortical activity in a biphasic manner. This is in close agreement with results obtained 
from previous studies with diazepam11, 14. The most convincing hypothesis to explain this biphasic depression is 
the existence of at least two benzodiazepine binding sites, as proposed by Walters et al., leading to two separate 
mechanisms of benzodiazepine action14.
The first phase of midazolam’s action (steady state of depression) is in line with previous studies18, 19 and this 
“ceiling effect” could be one of the reasons for the clinical safety of benzodiazepines. There are, however, several 
possibilities to explain this finding: First, a saturation at the classical benzodiazepine site11 and second, a novel 
binding site for benzodiazepines at the GABAA receptor, preventing further depression, as suggested in a previous 
study by Baur et al.20.
In accordance with previous clinical investigations and in vivo studies showing that sedation and changes 
of EEG frequencies could be induced by 1-hydroxymidazolam alone1, 2, 21 we found that 1-hydroxymidazolam 
inhibits neocortical network firing.
When comparing midazolam with 1-hydroxymidazolam it is evident that 1-hydroxymidazolam is far less 
potent. Inhibitory actions of 1-hydroxymidazolam could be observed starting at a concentration of 100 nM, 
Figure 4. Comparison of the effects of midazolam and 1-hydroxymidazolam in neocortical slice cultures 
from wild-type mice. (A) Combined presentation of the effect of midazolam (black, taken from Fig. 1A) and 
1-hydroxymidazolam (grey, taken from Fig. 2A) on the normalized action potential firing rate for comparison 
of actions. Data were fit as described in the methods section. Measures of statistical dispersion have been 
omitted for clarity reasons. Note that the two curves are shifted by roughly one order of magnitude. (B) Actions 
of midazolam and 1-hydroxymidazolam on the duration of phases of high neuronal activity (up state length). 
Data were also normalized to the median of the ASCF sham application (given by the dashed line). Midazolam 
significantly reduced the up state length between 5 nM and 100 nM. However, this effect was absent at 500 nM 
and 1 μM midazolam (*p < 0.001; Kruskal-Wallis test, post-hoc analysis (Bonferroni)). In comparison, 
1-hydroxymidazolam significantly shortened the up state length starting at 500 nM (Kruskal-Wallis test, post-
hoc analysis (Bonferroni)).
www.nature.com/scientificreports/
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corresponding to a plasma concentration of nearly 40 ng/ml. Considering the plasma concentration measured in 
a previous study3, 1-hydroxymidazolam may, therefore, contribute to the effects of midazolam, above all, in cases 
of deep sedation or in patients with severe renal dysfunction22. A summary of clinical and experimental findings 
concerning effects of midazolam and 1-hydroxymidazolam at different concentrations can be found in Table 1.
In addition, we detected that midazolam administered at the low concentration of 5 nM caused a significant 
inhibition of the cortical network activity in cultures from wild-type, but not from α1(H101R)knock-in mice. 
Therefore it seems reasonable to assume that midazolam at low nanomolar concentrations predominantly acts via 
α1-containing GABAA receptors. Thus, despite being a non-GABAA receptor subtype-selective benzodiazepine23, 
midazolam’s sedative actions are largely mediated by α1-containing GABAA receptors. In contrast to diazepam, at 
recombinant receptors midazaolam displays a preference for α1-containing GABAA receptors over α2-containing 
GABAA receptors: a recent study showed an approximately two-fold larger potentiation of GABA-induced cur-
rents by midazolam at GABAA receptors containing α1-subunits compared with GABAA receptors containing 
α2-subunits, whereas diazepam potentiated both receptor subtypes to a similar extent16.
Figure 5. Effects of midazolam and 1-hydroxymidazolam on phasic and tonic currents of cultured cortical 
neurons. (A) Raw traces from two example whole cell recordings in neocortical neurons are displayed. Upper 
two traces: Control condition and presence of 50 nM midazolam. Midazolam induced a slight broadening, a 
slight increase in amplitude and a slight increase in frequency of IPSCs. Lower two traces: Control condition 
and presence of 50 nM 1-hydroxymidazolam. The effect of 1-hydroxymidazolam resembles the combined 
effect of midazolam, but overall was less pronounced. (B) Summary of the actions of midazolam and 
1-hydroxymidazolam on IPSCs. The total charge transfer was calculated as area under the curve of the averaged 
IPSC multiplied by the frequency of IPSCs, normalized to control condition. At 50 nM the effect of midazolam 
on the total charge transfer is significantly different from sham application (n = 11, p = 0.046), while the effect 
of 1-hydroxymidazolam is not (n = 15, p = 0.022). (C) Raw traces from whole cell recordings illustrating 
the actions of midazolam and 1-hydroxymidazolam on tonic currents. Each recording shows 180 s starting 
at the application of 20 µM bicuculline. Top trace: Sham (ACSF) application plus bicuculline. Middle trace: 
Application of 50 nM midazolam plus bicuculline. Lower trace: Application of 50 nM 1-hydroxymidazolam 
plus bicuculline. Note that in each case a small tonic current is visible in the presence of bicuculline. (D) 
Summary of the actions of midazolam and 1-hydroxymidazolam on tonic inhibition. Both, midazolam and 
1-hydroxymidazolam at a concentration of 50 nM induced a tonic current in cultured cortical neurons in 
the presence of 20 µM bicuculline. However, tonic currents by midazolam (n = 9) and 1-hydroxymidazolam 
(n = 12) were not significantly different from sham application (n = 7).
www.nature.com/scientificreports/
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Figure 6. The actions of midazolam on global neuronal activity of organotypic slice cultures from GABAA 
receptor α1(H101R)knock-in mice. (A) Comparison of neuronal activity of wild-type mice (dark blue) and 
α1(H101R)knock-in mice (green) under control conditions. No difference between the two genotypes could 
be detected. (B) Actions of 5 nM midazolam (red) versus control condition (green) in slices from α1(H101R)
knock-in mice. Unlike in the wild-type mice, midazolam’s effect was absent in neocortical cultures from 
α1(H101R)knock-in mice. (C) Effect of 100 nM midazolam (red) versus control conditions (green). Only at this 
higher concentration midazolam depressed cortical activity also in cultures from α1(H101R)knock-in mice. 
(D) Depression of the overall action potential firing rate by midazolam in neocortical cultures from α1(H101R)
knock-in mice. In contrast to wild-type slice cultures (see Fig. 1A) the spontaneous firing rate was significantly 
depressed only at 100 nM and 1 µM (*p < 0.001; Kruskal-Wallis test, post-hoc analysis (Bonferroni) followed by 
Mann-Whitney U test). (E) A comparison of the concentration-dependant actions of midazolam in neocortical 
cultures from wild-type mice (grey) and α1(H101R)knock-in mice (black) given as median and the 95% CI. 
Note that both curves run nearly parallel.
www.nature.com/scientificreports/
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To date, α1-containing GABAA receptors have been shown to be of major importance for mediating sedation, 
amnesia and anticonvulsant activity of benzodiazepines16, 24. Due to midazolam’s high efficacy at this GABAA 
receptor subtype, changes in quantity or distribution of this receptor subtype might have some clinical implica-
tions. For example, there is growing evidence that inflammation changes GABAA receptor composition in the 
brain. Pribiag and Stellwagen demonstrated that TNFα decreases inhibitory synaptic strength by downregu-
lation of cell-surface levels of GABAA receptors25. In addition, interleukin-1β increases surface expression of 
α5-containing GABAA receptors and a tonic current generated by these receptors, resulting in memory deficits26. 
Furthermore, it is known that assembling, trafficking, clustering and endocytosis of GABAA receptors are highly 
dynamic and, thus, can be influenced by other factors like repeated seizures or alcohol abuse27. These changes 
in GABAA receptor populations might well be contributing to the high variability of duration and the different 
qualities of sedation with midazolam. Considering that midazolam shows a preference especially for α1-subunit 
containing GABAA receptors, small changes in the cell surface concentration of this GABAA receptor subtype may 
have major implications for midazolam’s clinical actions.
Moreover, there is evidence indicating that the addictive properties of benzodiazepines are mediated via 
α1-containing GABAA receptors28, 29. Finally, α1-subunits containing GABAA receptors are involved in devel-
opmental plasticity. The present ex vivo results raise questions regarding the potential induction of undesired 
long-term changes by midazolam in immature neuronal networks30.
In summary, midazolam depresses cortical networks at the low concentration of 5 nM, predominantly medi-
ated via α1-containing GABAA receptors. This GABAA receptor subtype is the major molecular target of benzodi-
azepines for sedation. Small changes of this receptor population, e.g., due to inflammatory diseases, may therefore 
serve as an explanation for the large variability of midazolam’s clinical properties.
Midazolam’s main metabolite, 1-hydroxymidazolam, is far less potent than midazolam itself. The qualitatively 
different actions of 1-hydroxymidazolam compared with those of midazolam might argue for differential affini-
ties of these two drugs at the α1 GABAA receptor subtype, possibly also at different GABAA receptor subtypes, as 
has recently been described for clobazam and its metabolite N-desmethyl-clobazam31.
We conclude that when considering the clinically relevant concentrations of midazolam, used for sedation 
in intensive care medicine, midazolam is clearly more potent than its metabolite, i.e. the major clinical effects 
are caused by the parent drug midazolam itself, presumably acting on cortical neurons. The higher potency of 
1-hydroxymidazolam seen in some in vivo studies could be due to other types of GABAA receptors in lower brain 
structures, i.e. δ-subunit containing GABAA receptors.
Methods
Organotypic slice cultures. All procedures were approved by the Animal Care Committee (Eberhard 
Karls University, Tübingen, Germany) and were in accordance with the institutional and federal guidelines of 
the German Animal Welfare Act (TierSchG). Wild-type C57BL/6J mice and GABAA receptor α1(H101R)mutant 
mice on C57BL/6J background15 of both sexes were used. Neocortical organotypic slice cultures were prepared 
from three to five day old mice as described before32. In brief, animals were deeply anaesthetized with isoflurane 
and then decapitated. Cortical hemispheres were removed aseptically and 300 µm thick coronal slices were cut. 
Slices were fixed on glass coverslips by means of a plasma clot, transferred into plastic tubes containing each 
750 µL of nutrition medium, to be then incubated in a roller drum at 37 °C. After 1 day in culture, antimitotics 
(10 µM 5-fluoro-2′-deoxyuridine, 10 μM ARA-c and 10 μM uridine) were added. The suspension was renewed 
twice a week.
Electrophysiology. Extracellular multi-unit recordings were performed in a recording chamber mounted 
on an inverted microscope. Slices were perfused with artificial cerebrospinal fluid (ACSF) consisting of (in mM) 
Predicted concentrations in the 
brain Light sedation Profound sedation
Induction of general 
anesthesia
midazolam + 1-hydroxymidazolam 50 nM + 30 nM1
670–
2440 nM + 100–
270 nM3
2400 nM + 200 nM42
1-hydroxymidazolam alone under 
experimental conditions
115–230 nM1 
500 nM in rats2 no data no data
Table 1. Predicted concentrations of midazolam and 1-hydroxymidazolam in the brain, corresponding 
to the level of sedation. The second row summarizes plasma concentrations taken from clinical studies, 
where 1-hydroxymidazolam is a product of metabolism of midazolam. The third row reports data where 
1-hydroxmidazolam was given alone, i.e., in the absence of midazolam. Meanwhile, a study by Bremer et al. 
demonstrated in critically ill patients plasma concentrations ranging from 60 to 136 ng/ml for midazolam and 
from 11 to 62.5 ng/ml for 1-hydroxymidazolam for lightly sedated patients as well as plasma concentrations 
ranging from 307 to 1106 ng/ml for midazolam and from 41 to 119 ng/ml for 1-hydroxymidazolam for deeply 
sedated patients3. Taking into account the molecular weights of the two compounds, midazolam’s free unbound 
fraction of approximately 3%1 and the brain-to-unbound-serum concentration ratio of almost 3443, this would 
correspond to a midazolam concentration of about 130 to 2,400 nM in the central nervous system. In the case 
of 1-hydroxymidazolam, the free unbound fraction is supposed to be 10%1 and the brain-to-unbound-serum 
concentration ratio around 843. Thus, the concentration of 1-hydroxymidazolam in the central nervous system 
should range from 25 to 270 nM. These assumptions are in accordance with data from the literature, indicating 
that nanomolar concentrations of midazolam in vitro are of clinical relevance18.
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NaCl 120, KCl 3.5, NaH2PO4 1.13, MgCl2 1.0, NaHCO3 26, CaCl2 1.2, and glucose 11; then bubbled with 95% 
oxygen and 5% carbon dioxide. All experiments were conducted at 34 °C. For this purpose, a heating wire was 
glued onto a metal frame of the recording chamber and then heated using a direct current. ACSF-filled glass 
electrodes with a resistance of 3 to 5 MΩ were advanced into the tissue until extracellular multi-unit spike activ-
ity exceeding 100 µV in amplitude was visible. Data were acquired with the digidata 1200 AD/DA interface and 
AxoScope 9 software.
Intracellular voltage clamp recordings were performed on visually identified pyramidal neurons at room tem-
perature. Pipettes were filled with a solution containing (in mM) 121 CsCL, 24 CsOH, 10 HEPES, 5 EGTA, 1 
MgCl2 and 4 ATP, adjusted to pH 7.2 with 1 N HCl. Cells were voltage-clamped at −70 mV. To suppress gluta-
matergic synaptic transmission, we added 25 µM D-L-2-amino-5-phosphonopentanoic acid, 10 µM 6-cyano-7
-nitroquinoxaline-2.3-dione and 1 µM tetrodotoxin. For the detection of tonic currents 20 µM bicuculline was 
added to the ACSF. Analysis of tonic currents followed the method proposed by Glykys and Mody33 and is 
described in detail in reference34.
Preparation and Application of Test Solutions. Midazolam and 1-hydroxymidazolam were dissolved 
in dimethyl sulfoxide to a 1 mM stock solution. Flumazenil was dissolved in 99% ethanol to a 5 mM stock solu-
tion. Drugs were diluted in ACSF to the tested concentration and filled into glass syringes immediately before 
the experiment was conducted. The drug containing ACSF was applied via bath perfusion using syringe pumps, 
connected to the experimental chamber via Teflon tubing. When switching from ACSF to drug-containing solu-
tions, the medium was replaced by at least 95% within two minutes. To ensure steady-state conditions, recordings 
were conducted 12 minutes after commencing the change of the perfusate. Previous studies have demonstrated 
that this time interval is sufficient for steady-state conditions35, 36 because diffusion times in slice cultures are 
considerably shorter compared to acute slice preparations37, 38.
Data Analysis. Extracellular recorded signals were filtered and counted offline using self-written Matlab 
(R2008b) routines. The activity pattern of neocortical slice cultures was characterized by phases of spontaneous 
action potential firing (up states) separated by periods of neuronal silence. Action potentials were detected and 
the average firing rate was computed, using an automated event detection algorithm with a threshold set approx-
imately 2 times higher than baseline noise. An up state was defined by an initial inter-event interval of 75 ms and 
a preceding silent period of at least 500 ms. All automated up state detection was checked by visual inspection 
based on field potentials. Parameters are shown as relative change compared to ACSF sham application. Each 
data set was checked for normal distribution by using qq plots. However, the hypothesis that data sets were nor-
mally distributed had to be rejected for the majority of these data sets. Therefore, grouped data are expressed as 
boxplots (line: median, box: lower quartile = 25th percentile and upper quartile = 75th percentile; whisker: 1.5*iqr 
(interquartile range); iqr: difference between the upper and the lower quartiles). For statistical analysis of extra-
cellular detected neuronal spiking activity, we performed a combination of a non-parametric analysis of variance 
(Kruskal-Wallis test) and a multiple comparison post-hoc analysis (Bonferroni), followed by a Mann-Whitney U 
test to check for significant differences between the two groups.
To illustrate changes of the network firing, especially during phases of high neuronal activity (up states) 
peri-event time histograms (PETH) were calculated. For this purpose, the up states of every experimental con-
dition were collected, divided into bins of 10 ms, and averaged. Because the length of up states was variable, the 
PETH were constrained to the first 1000 ms. To test for statistically significant effects, the effect size (Hedges’ g 
including the 95% confidence interval) was calculated. The 95% confidence interval excluding zero indicates 
significance at p < 0.05. A general rule of thumb says that absolute Hedges’ g values >0.8 indicate a strong effect 
and values >0.5 indicate a medium effect.
Statistical comparison of the actions of midazolam and 1-hydroxymidazolam. An extra 
sums-of-squares F test39 was performed to statistically compare IC50 values of the concentration-response rela-
tions of normalized firing rates for midazolam and 1-hydroxymidazolam. The underlying null hypothesis was that 
both data sets (midazolam and 1-hydroxymidazolam) stemmed from concentration-response relations with the 
same IC50. Briefly, Hill functions with three and two free parameters (‘full’ and ‘constrained’ models, respectively) 
were each fitted to each data set. In the constrained model, the IC50 (Kd) value was set to a fixed value, determined 
from a full Hill fit to the union of both data sets. An F value was computed as F = (SS1-SS2)/(DF1-DF2)/(SS2/
DF2) where SS1 is the sum-of-squares of the constrained model (summed for both data sets), DF1 the degrees of 
freedom of the constrained model (again summed for both data sets), and SS2 and DF2 the equivalent values of 
the full model. From this F value (with DF1-DF2 and DF2 degrees of freedom for the numerator and denomina-
tor, respectively) a p value was computed, which specified the probability of obtaining data sets at least as extreme 
as the measured samples, given the null hypothesis.
As midazolam and 1-hydroxymidazolam altered up state length in qualitatively different ways, a fitting 
approach for statistical comparison of both drugs’ effects was not deemed reasonable. Instead, we opted for a 
two-way analysis of variance (ANOVA) with drug type (midazolam and 1-hydroxymidazolam) and drug concen-
tration as the independent factors, focusing on their interaction. We computed both the p-value and eta squared, 
a measure of effect size, for the interaction of drug type with drug concentration. 95% confidence intervals of eta 
squared were computed by bootstrapping. Prior to analysis via ANOVA, the data were Box-Cox-transformed40 
as the distribution of normalized burst length often had long tails towards high values: for each concentration of 
both drugs, the transformation parameter lambda was estimated; from the resulting collection of lambda values 
an average weighted by the number of samples in each group was computed (lambda = 0.214) and all data trans-
formed with this value.
All analyses were implemented in Matlab (R2016b) and partly made use of the measure of effect size toolbox41.
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